Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

Suzette Girgis,Shun Xin Wang Lin,Kodandaram Pillarisetti,Raluca Verona,Diego Vieyra,Tineke Casneuf,Damien Fink,Xin Miao,Yang Chen,Tara Stephenson,Arnob Banerjee,Brandi Hilder,Jeffery Scott Russell,Jennifer Smit,Jenna D. Goldberg

Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

2021

Suzette Girgis
Shun Xin Wang Lin
Kodandaram Pillarisetti
Raluca Verona
Diego Vieyra
Tineke Casneuf
Damien Fink
Xin Miao
Yang Chen
Tara Stephenson
Arnob Banerjee
Brandi Hilder
Jeffery Scott Russell
Jennifer Smit
Jenna D. Goldberg

8047Background: B-cell maturation antigen (BCMA, CD269) is a single transmembrane protein that is selectively expressed in the B-cell lineage and is a validated target for multiple myeloma. BCMA ex...

Keywords:

Medicine
Transmembrane protein
Antigen
in patient
B-Cell Maturation Antigen
Cancer research
Refractory Multiple Myeloma
lineage
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations